论文部分内容阅读
目的:探讨n 99Tcn m标记抗程序性死亡受体1配体(PD-L1)纳米抗体(NM-01)的SPECT/CT显像探测非小细胞肺癌(NSCLC)PD-L1表达的价值。n 方法:前瞻性纳入2019年1月至2020年3月间于上海交通大学附属第一人民医院病理确诊为NSCLC且未经治疗的患者14例[男11例，女3例，年龄(61.9±11.0)岁]。用放射性核素n 99Tcn m标记NM-01，患者注射n 99Tcn m-NM-01[剂量为(359.1±68.0) MBq]后2 h进行定量SPECT/CT显像。采用两独立样本n t检验比较PD-L1阳性和PD-L1阴性患者的SUVn max差异，采用Pearson相关分析原发灶SUVn max与PD-L1表达的相关性。n 结果:14例患者中，PD-L1阳性6例，PD-L1阴性8例。n 99Tcn m-NM-01在肝、肾中有明显摄取，在脾和骨髓中也有轻微摄取。n 99Tcn m-NM-01注射后2 h原发灶的SUVn max为4.69±1.88，转移灶的SUVn max为2.04±1.32。PD-L1阳性患者原发灶的SUVn max明显高于PD-L1阴性患者，差异具有统计学意义(5.99±1.99和3.72±1.10；n t＝5.98，n P＝0.039)；但2组间转移灶的SUVn max差异无统计学意义(1.66±1.03和2.35±1.46；n t＝-1.77，n P＝0.084)。原发灶的SUVn max与PD-L1表达水平呈正相关(n r＝0.648，n P＝0.042)。n 结论:99Tcn m-NM-01能够显示NSCLC原发灶和转移灶的PD-L1表达水平。n “,”Objective:To explore the value of SPECT/CT imaging on programmed death receptor 1 ligand (PD-L1) expression in patients with non-small cell lung cancer (NSCLC) based on n 99Tcn m labeled anti-PD-L1 nanoantibodies (NM-01).n Methods:From January 2019 to March 2020, a total of 14 patients (11 males, 3 females; age: (61.9±11.0) years) with pathologically confirmed NSCLC in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine were prospectively enrolled. NM-01 were labeled with n 99Tcn m, and patients were recruited for SPECT/CT imaging 2 h after injection with n 99Tcn m-NM-01((359.1±68.0) MBq). The differences of SUVn max in primary and metastatic lesions between PD-L1 positive and negative patients were compared by independent sample n t test. The correlation between the SUVn max and PD-L1 expression of primary lesions was analyzed by Pearson correlation analysis.n Results:Of 14 patients, 6 were PD-L1 positive and 8 were PD-L1 negative. n 99Tcn m-NM-01 showed obviously increased uptake in kidneys and liver, while mildly increased uptake in spleen and bone marrow. The SUVn max of primary lesions was 4.69±1.88 and the SUVn max of metastatic lesions was 2.04±1.32. The SUVn max of primary lesions in PD-L1 positive patients was significantly higher than that of PD-L1 negative patients (5.99±1.99 n vs 3.72±1.10; n t=5.98, n P=0.039). There was no significant difference in the SUVn max of metastatic lesions between PD-L1 positive and negative patients (1.66±1.03 n vs 2.35±1.46; n t=-1.77, n P=0.084). The SUVn max of primary lesions was positively correlated with PD-L1 expression (n r=0.648, n P=0.042).n Conclusion:99Tcn m-NM-01 can demonstrate the expression of PD-L1 in primary and metastatic lesions in NSCLC.n